68O EFFICACY, SAFETY AND TOLERABILITY RESULTS FROM A PHASE IV, OPEN-LABEL, SINGLE ARM STUDY OF 1ST-LINE GEFITINIB IN CAUCASIAN PATIENTS (PTS) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

✍ Scribed by Douillard, J.; Ostoros, G.; Cobo, M.; Ciuleanu, T.; McCormack, R.; Webster, A.; Milenkova, T.

• Book ID: 122757719
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 45 KB
• Volume: 80
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/S0169-5002(13)70288-5